Cargando…

COVID-19 and Sickle Cell Disease in the Province of Quebec, Canada: Outcomes after Two Years of the Pandemic

Background: Patients with sickle cell disease (SCD) are considered at higher risk of severe COVID-19 infection. However, morbidity and mortality rates are variable among countries. To date, there are no published reports that document outcomes of SCD patients with COVID-19 in Canada. Methods: A web-...

Descripción completa

Detalles Bibliográficos
Autores principales: Castonguay, Mathias, Dakhallah, Nawar, Desroches, Justin, Colaiacovo, Marie-Laure, Jimenez-Cortes, Camille, Claveau, Anne-Marie, Bérubé, Samuel, Hafsaoui, Amer Yassine, Souza, Amalia, Tibout, Pauline, Ah-Yan, Christophe, Vincent, Anne-Marie, Naessens, Veronique, Brossard, Josée, Abish, Sharon, Santiago, Raoul, Soulières, Denis, Laroche, Vincent, Pastore, Yves, Tran, Thai Hoa, Forté, Stéphanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781039/
https://www.ncbi.nlm.nih.gov/pubmed/36555978
http://dx.doi.org/10.3390/jcm11247361
_version_ 1784856975973023744
author Castonguay, Mathias
Dakhallah, Nawar
Desroches, Justin
Colaiacovo, Marie-Laure
Jimenez-Cortes, Camille
Claveau, Anne-Marie
Bérubé, Samuel
Hafsaoui, Amer Yassine
Souza, Amalia
Tibout, Pauline
Ah-Yan, Christophe
Vincent, Anne-Marie
Naessens, Veronique
Brossard, Josée
Abish, Sharon
Santiago, Raoul
Soulières, Denis
Laroche, Vincent
Pastore, Yves
Tran, Thai Hoa
Forté, Stéphanie
author_facet Castonguay, Mathias
Dakhallah, Nawar
Desroches, Justin
Colaiacovo, Marie-Laure
Jimenez-Cortes, Camille
Claveau, Anne-Marie
Bérubé, Samuel
Hafsaoui, Amer Yassine
Souza, Amalia
Tibout, Pauline
Ah-Yan, Christophe
Vincent, Anne-Marie
Naessens, Veronique
Brossard, Josée
Abish, Sharon
Santiago, Raoul
Soulières, Denis
Laroche, Vincent
Pastore, Yves
Tran, Thai Hoa
Forté, Stéphanie
author_sort Castonguay, Mathias
collection PubMed
description Background: Patients with sickle cell disease (SCD) are considered at higher risk of severe COVID-19 infection. However, morbidity and mortality rates are variable among countries. To date, there are no published reports that document outcomes of SCD patients with COVID-19 in Canada. Methods: A web-based registry was implemented in June 2020 capturing outcomes of SCD patients with COVID-19 from March 2020 to April 2022 and comparing them to the general population of Quebec, Canada. Results: After 24 months of the pandemic, 185 SCD patients with confirmed SARS-CoV-2 infection were included in the registry. Overall, the population was young (median age 12 years old) and had few comorbidities. No deaths were reported. Risk of hospitalization and admission to intensive care unit (ICU) because of COVID-19 was higher in patients with SCD than in the general population (relative risks (RR) 5.15 (95% confidence interval (95% CI) 3.84–6.91), p ˂ 0.001 and 4.56 (95% CI 2.09–9.93) p ˂ 0.001). A history of arterial hypertension or acute chest syndrome in the past 12 months was associated with a higher risk of severe disease (RR = 3.06 (95% CI 1.85–5.06) p = 0.008 and 2.27 (95% CI 1.35–3.83) p = 0.01). Hospitalized patients had lower hemoglobin F than non-hospitalized patients (12% vs. 17%, p = 0.02). For those who had access to vaccination at the time of infection, 25 out of 26 patients were adequately vaccinated and had mild disease. Conclusions: The SCD population is at higher risk of severe disease than the general population. However, we report favorable outcomes as no deaths occurred. Registries will continue to be critical to document the impact of novel COVID-19 specific therapy and vaccines for the SCD population.
format Online
Article
Text
id pubmed-9781039
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97810392022-12-24 COVID-19 and Sickle Cell Disease in the Province of Quebec, Canada: Outcomes after Two Years of the Pandemic Castonguay, Mathias Dakhallah, Nawar Desroches, Justin Colaiacovo, Marie-Laure Jimenez-Cortes, Camille Claveau, Anne-Marie Bérubé, Samuel Hafsaoui, Amer Yassine Souza, Amalia Tibout, Pauline Ah-Yan, Christophe Vincent, Anne-Marie Naessens, Veronique Brossard, Josée Abish, Sharon Santiago, Raoul Soulières, Denis Laroche, Vincent Pastore, Yves Tran, Thai Hoa Forté, Stéphanie J Clin Med Article Background: Patients with sickle cell disease (SCD) are considered at higher risk of severe COVID-19 infection. However, morbidity and mortality rates are variable among countries. To date, there are no published reports that document outcomes of SCD patients with COVID-19 in Canada. Methods: A web-based registry was implemented in June 2020 capturing outcomes of SCD patients with COVID-19 from March 2020 to April 2022 and comparing them to the general population of Quebec, Canada. Results: After 24 months of the pandemic, 185 SCD patients with confirmed SARS-CoV-2 infection were included in the registry. Overall, the population was young (median age 12 years old) and had few comorbidities. No deaths were reported. Risk of hospitalization and admission to intensive care unit (ICU) because of COVID-19 was higher in patients with SCD than in the general population (relative risks (RR) 5.15 (95% confidence interval (95% CI) 3.84–6.91), p ˂ 0.001 and 4.56 (95% CI 2.09–9.93) p ˂ 0.001). A history of arterial hypertension or acute chest syndrome in the past 12 months was associated with a higher risk of severe disease (RR = 3.06 (95% CI 1.85–5.06) p = 0.008 and 2.27 (95% CI 1.35–3.83) p = 0.01). Hospitalized patients had lower hemoglobin F than non-hospitalized patients (12% vs. 17%, p = 0.02). For those who had access to vaccination at the time of infection, 25 out of 26 patients were adequately vaccinated and had mild disease. Conclusions: The SCD population is at higher risk of severe disease than the general population. However, we report favorable outcomes as no deaths occurred. Registries will continue to be critical to document the impact of novel COVID-19 specific therapy and vaccines for the SCD population. MDPI 2022-12-12 /pmc/articles/PMC9781039/ /pubmed/36555978 http://dx.doi.org/10.3390/jcm11247361 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Castonguay, Mathias
Dakhallah, Nawar
Desroches, Justin
Colaiacovo, Marie-Laure
Jimenez-Cortes, Camille
Claveau, Anne-Marie
Bérubé, Samuel
Hafsaoui, Amer Yassine
Souza, Amalia
Tibout, Pauline
Ah-Yan, Christophe
Vincent, Anne-Marie
Naessens, Veronique
Brossard, Josée
Abish, Sharon
Santiago, Raoul
Soulières, Denis
Laroche, Vincent
Pastore, Yves
Tran, Thai Hoa
Forté, Stéphanie
COVID-19 and Sickle Cell Disease in the Province of Quebec, Canada: Outcomes after Two Years of the Pandemic
title COVID-19 and Sickle Cell Disease in the Province of Quebec, Canada: Outcomes after Two Years of the Pandemic
title_full COVID-19 and Sickle Cell Disease in the Province of Quebec, Canada: Outcomes after Two Years of the Pandemic
title_fullStr COVID-19 and Sickle Cell Disease in the Province of Quebec, Canada: Outcomes after Two Years of the Pandemic
title_full_unstemmed COVID-19 and Sickle Cell Disease in the Province of Quebec, Canada: Outcomes after Two Years of the Pandemic
title_short COVID-19 and Sickle Cell Disease in the Province of Quebec, Canada: Outcomes after Two Years of the Pandemic
title_sort covid-19 and sickle cell disease in the province of quebec, canada: outcomes after two years of the pandemic
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781039/
https://www.ncbi.nlm.nih.gov/pubmed/36555978
http://dx.doi.org/10.3390/jcm11247361
work_keys_str_mv AT castonguaymathias covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic
AT dakhallahnawar covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic
AT desrochesjustin covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic
AT colaiacovomarielaure covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic
AT jimenezcortescamille covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic
AT claveauannemarie covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic
AT berubesamuel covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic
AT hafsaouiameryassine covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic
AT souzaamalia covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic
AT tiboutpauline covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic
AT ahyanchristophe covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic
AT vincentannemarie covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic
AT naessensveronique covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic
AT brossardjosee covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic
AT abishsharon covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic
AT santiagoraoul covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic
AT soulieresdenis covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic
AT larochevincent covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic
AT pastoreyves covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic
AT tranthaihoa covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic
AT fortestephanie covid19andsicklecelldiseaseintheprovinceofquebeccanadaoutcomesaftertwoyearsofthepandemic